( MENAFN - GlobeNewsWire - Nasdaq) LAKE FOREST, Ill., June 06, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the“Company”) (NASDAQ: ASRT), a Pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective May 31, 2024, the Compensation Committee of the Company's Board of Directors granted the Company's new Chief Executive Officer, Brendan P.
O'Grady, 500,000 restricted stock units (“RSUs”) and 1,800,000 stock options (“options”). The RSUs and options were granted as inducements material to Mr. O'Grady's entry into employment with Assertio in accordance with NASDAQ Listing Rule 5635(c)(4).
The RSUs and options are subject to his continued service relationship with the Company, terms and conditions substantially identical to those set forth in the Company's 2014 Omnibus Incentive Plan and the award agreements pursuant to which they were granted. The options have an exercise price of $0.99 per share, which is equal to the closing price of Assertio's common stock on the grant date.
The RSUs and options vest equally annually over three years beginning on the first anniversary of the grant date. About Assertio Assertio is a commercial pharmaceutical company offering differentiated products to patients. We have built our commercial portfolio through acquisition or licensing of approved products.
Our comprehensive commercial capabilities include marketing through both a sales fo.
